Published on in Vol 8, No 3 (2022): March

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/33191, first published .
The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study

The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study

The Disease and Economic Burdens of Esophageal Cancer in China from 2013 to 2030: Dynamic Cohort Modeling Study

Journals

  1. Su N, Mok L, Chan M, Liu H, Chang W, Yun C, Shieh T, Wu M, Lin H, Huang W, Chen Y. Impact of Perineural Invasion and Preexisting Type 2 Diabetes on Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Chemoradiotherapy. Cancers 2023;15(4):1122 View
  2. Zhang X, Wang H, He D, He M, Chen X, Zhao J, Shi Z. Posttreatment Recurrence and Death Patterns in Patients with Advanced Esophageal Cancer. Disease Markers 2022;2022:1 View
  3. Zhang H, Fu Y, Chen M, Si L. Socioeconomic inequality in health care use among cancer patients in China: Evidence from the China health and retirement longitudinal study. Frontiers in Public Health 2022;10 View
  4. Han Y, Zhu X, Hu Y, Yu C, Guo Y, Hang D, Pang Y, Pei P, Ma H, Sun D, Yang L, Chen Y, Du H, Yu M, Chen J, Chen Z, Huo D, Jin G, Lv J, Hu Z, Shen H, Li L. Electronic Health Record–Based Absolute Risk Prediction Model for Esophageal Cancer in the Chinese Population: Model Development and External Validation. JMIR Public Health and Surveillance 2023;9:e43725 View
  5. Song X, Feng X, Chen S, Dai Y, Huang H, Li X, Yu P, Li J, Yi J, Zhao Y, Chen W, Ni Y, Zhu S, Zhang Z, Xia L, Zhang J, Yang S, Ni J, Lu H, Wang Z, Nie S, Wu Y, Liu L. Potential impact of time trend of whole grain intake on burden of major cancers in China. Preventive Medicine 2023;175:107674 View
  6. Li P, Jing J, Liu W, Wang J, Qi X, Zhang G. Spatiotemporal Patterns of Esophageal Cancer Burden Attributable to Behavioral, Metabolic, and Dietary Risk Factors From 1990 to 2019: Longitudinal Observational Study. JMIR Public Health and Surveillance 2023;9:e46051 View
  7. Yu Z, Bai X, Zhou R, Ruan G, Guo M, Han W, Jiang S, Yang H. Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019. International Journal of Cancer 2024;154(4):615 View
  8. Zheng H, Li J, Wen F, Su N. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma. Frontiers in Oncology 2023;13 View
  9. Zhou C, Wei J, Xu K, Lin Y, Zhang L, Li X. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China. Risk Management and Healthcare Policy 2023;Volume 16:2447 View
  10. Li H, Teng Y, Yan X, Cao M, Yang F, He S, Zhang S, Li Q, Xia C, Li K, Chen W. Profiles and Findings of Population-Based Esophageal Cancer Screening With Endoscopy in China: Systematic Review and Meta-analysis. JMIR Public Health and Surveillance 2023;9:e45360 View
  11. Jia S, Chen Y, Cui J, Wang T, Lin C. Relationship of weight loss to quality of life and symptom distress among postsurgical survivors of oesophageal cancer who received chemotherapy. European Journal of Oncology Nursing 2023;66:102370 View
  12. Zheng Z, Fang L, Cai H, Zhu H. Cost–effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma. Immunotherapy 2023;15(13):1045 View
  13. Chen Y, Zhao Y, Liu J, Teng Y, Ou M, Hao X. Predictive value of perioperative procalcitonin, C reactive protein and high-sensitivity C reactive protein for the risk of postoperative complications after non-cardiac surgery in elderly patients: a nested case–control study. BMJ Open 2023;13(10):e071464 View
  14. Guo H, Wang Q, Wang C, Yin Q, Huo H, Yin B. Secular Trends in Gastric and Esophageal Cancer Attributable to Dietary Carcinogens From 1990 to 2019 and Projections Until 2044 in China: Population-Based Study. JMIR Public Health and Surveillance 2023;9:e48449 View
  15. Chen F, Long Y, Yang J, Zhong K, Liu B. Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China. BMJ Open 2023;13(12):e078924 View
  16. Jiang Q, Shu Y, Jiang Z, Zhang Y, Pan S, Jiang W, Liang J, Cheng X, Xu Z. Burdens of stomach and esophageal cancer from 1990 to 2019 and projection to 2030 in China: Findings from the 2019 Global Burden of Disease Study. Journal of Global Health 2024;14 View
  17. Li J, Xu C, Yuan S. A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial. Cost Effectiveness and Resource Allocation 2024;22(1) View